JIGAR YOG‘LI GEPATOZIDA HUJAYRALARDA KECHADIGAN PATOFIZIOLOGIK O‘ZGARISHLAR
Keywords:
Jigar yog‘li gepatozi, hepatotsit, triglitseridlar, oksidlovchi stress, mitoxondrial disfunksiya, yallig‘lanish, apoptoz, lipotoksiklik, endoplazmatik retikulum stresi, insulinrezistentlik.Abstract
Mazkur maqolada jigar yog‘li gepatozi rivojlanishida hepatotsitlarda kuzatiladigan patofiziologik o‘zgarishlar tahlil qilinadi. Unda hujayra darajasida triglitseridlar to‘planishi, mitoxondrial disfunksiya, oksidlovchi stress, endoplazmatik retikulum stressi, yallig‘lanish mediatorlari faollashuvi va apoptoz jarayonlarining kuchayishi kabi asosiy mexanizmlar yoritilgan. Shuningdek, kasallikning progressiv kechishiga olib keluvchi molekulyar omillar va hujayraviy jarayonlarning o‘zaro bog‘liqligi ilmiy manbalar asosida bayon etilgan.
References
1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(S1):S99–S112.
2. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial dysfunction in nonalcoholic fatty liver disease: from pathogenesis to therapeutic opportunities. J Hepatol. 2013;58(4): 781–790.
3. Sanyal AJ. Oxidative stress and non-alcoholic fatty liver disease. Clin Liver Dis. 2004;8(4):739–762.
4. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol. 2011;54(4):795–809.
5. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–1846.
6. Schattenberg JM, Galle PR. Apoptosis in liver disease. Clin Liver Dis. 2006;10(3): 627–645.
7. PubMed Database. Search terms: “fatty liver”, “hepatic steatosis”, “hepatocyte pathophysiology”. Accessed 2025.
8. Scopus Database. Search terms: “oxidative stress in hepatocytes”, “ER stress fatty liver”. Accessed 2025.
9. Web of Science. Search terms: “apoptosis liver steatosis”, “inflammation in NAFLD”. Accessed 2025.
10. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011;7(8):456–465.
11. Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for new therapies. J Hepatol. 2013;59(1):33–42.
12. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.
13. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679–689.
14. Begriche K, Massart J, Robin MA, et al. Mitochondrial adaptations and dysfunction in NAFLD. J Hepatol. 2013;58(4):781–790.
15. Sanyal AJ. Mechanisms of disease: oxidative stress in NAFLD. Nat Clin Pract Gastroenterol Hepatol. 2005;2(8):402–409.
16. Malhi H, Kaufman RJ. ER stress and hepatocyte injury. J Hepatol. 2011;54(4):795–809.
17. Tilg H, Moschen AR. Cytokines in NAFLD: TNF-alpha, IL-6. Hepatology. 2010;52(5):1836–1846.
18. Schattenberg JM, Galle PR. Hepatocyte apoptosis in NAFLD progression. Clin Liver Dis. 2006;10(3):627–645.
